



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Fluocinolone acetonide intravitreal implant (Iluvien®)
Indication under review	NICE TA 301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Policy No:	APC 034
Date of Issue:	January 2014
Review Date:	January 2017
Policy Statement: Fluocinolone is recommended as an option for treating DMO in secondary care when used in accordance with NICE TA 301, see points below.	
Traffic Light Status	Red
Key Points considered: <ul style="list-style-type: none">• Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if:• the implant is to be used in an eye with an intraocular (pseudophakic) lens and• the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.	
References: NICE TA 301 accessible via http://guidance.nice.org.uk/TA301/Guidance/pdf/English	
Date taken to APC:	8 th January 2014
Date Ratified by GP MMC on Behalf of the Board:	15 th January 2014